Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Benzimidazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | QPCT | Q16769 | 2/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL28221038 | 0.91 | KDM4E (0.42) | PRKCIKDM4EMAPTRAD52ALDH1A1 | |
| Benzimidazole SCHEMBL2334176 | 0.90 | PRKCI (0.50) | PRKCIKDM4EMAPTRAD52ALDH1A1 | |
| Benzimidazole SCHEMBL4371075 | 0.88 | KDM4E (0.51) | PRKCIKDM4EMAPTRAD52ALDH1A1 | |
| Benzimidazole SCHEMBL5070094 | 0.88 | KDM4E (0.51) | PRKCIKDM4EMAPTRAD52ALDH1A1 | |
| Benzimidazole SCHEMBL28800549 | 0.88 | PRKCI (0.46) | PRKCIKDM4EMAPTRAD52ALDH1A1 | |
| Benzimidazole SCHEMBL5404384 | 0.87 | PRKCI (0.52) | PRKCIKDM4EMAPTRAD52ALDH1A1 | |
| Benzimidazole SCHEMBL10931770 | 0.87 | SMN1; SMN2 (0.50) | PRKCIKDM4EMAPTRAD52ALDH1A1 | |
| Benzimidazole SCHEMBL6009 | 0.87 | — | — | |
| Benzimidazole SCHEMBL29408372 | 0.87 | — | — | |
| Benzimidazole SCHEMBL29358377 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117051587-A | Preparation process of washable efficient antibacterial polyester fabric | 潮州市丹辉婚纱礼服有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-117051587-A | Preparation process of washable efficient antibacterial polyester fabric | 潮州市丹辉婚纱礼服有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-117051587-A | Preparation process of washable efficient antibacterial polyester fabric | 潮州市丹辉婚纱礼服有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-10753947-B2 | Methods for screening voltage-gated proteins | D.E. SHAW RESEARCH, LLC (US) | 2020-08-25 | — | — | US | disclosed |
| US-10739354-B2 | Methods for screening voltage-gated proteins | D.E. SHAW RESEARCH, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-10647735-B2 | Metal complexes and methods of preparing the same | UNIVERSITY OF NEW BRUNSWICK (CA) | 2020-05-12 | — | — | US | disclosed |
| US-20200017535-A1 | METAL COMPLEXES AND METHODS OF PREPARING THE SAME | UNIVERSITY OF NEW BRUNSWICK (CA) | 2020-01-16 | — | — | US | disclosed |
| US-20170115309-A1 | METHODS FOR SCREENING VOLTAGE-GATED PROTEINS | D.E. SHAW RESEARCH, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20150087552-A1 | METHODS FOR SCREENING VOLTAGE-GATED PROTEINS | D.E. SHAW RESEARCH, LLC | 2015-03-26 | — | — | US | disclosed |
| CN-101263256-B | Amphoteric stilbene composition | HEWLETT PACKARD DEVELOPMENT CO | 2011-07-06 | — | — | CN | disclosed |
| CN-101263256-A | Amphoteric stilbene composition | HEWLETT PACKARD DEVELOPMENT CO (US) | 2008-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647735-B2 | Metal complexes and methods of preparing the same | CACYBP, CLTB, VDAC2 | PRKCI 3883/4885KDM4E 3520/4885MAPT 1777/4885 |
| US-20200017535-A1 | METAL COMPLEXES AND METHODS OF PREPARING THE SAME | CACYBP, CLTB, VDAC2 | PRKCI 3883/4885KDM4E 3520/4885MAPT 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.